GlassScriptPhysician profile
Barbara L Moersch
NPI 1437127867
$2,352.76
in general payments reported to CMS, 2019-2025
29 companies · $549 in 2025
The $549 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $122 · 2021: $373 · 2022: $215 · 2023: $531 · 2024: $339 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.97 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $574.57 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $298.14 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $286.53 | 2024-2025 | Gemtesa, Myfembree |
| Mayne Pharma Commercial LLC | $172.34 | 2021-2025 | |
| Therapeuticsmd, INC. | $131.51 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $102.01 | 2019-2022 | |
| Ethicon US, LLC | $79.77 | 2021-2024 | Surgiflo Hemostatic Matrix, Vistaseal |
| Exact Sciences Corporation | $76.14 | 2024-2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $59.08 | 2021-2023 | Slynd |
| Samsung Hme America, INC. | $58.76 | 2022 | |
| Avion Pharmaceuticals | $56.83 | 2019-2021 | |
| Sage Therapeutics, LLC | $51.84 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $48.61 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.69 | 2025 | |
| Shield Therapeutics INC | $38.77 | 2023-2024 | Accrufer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $37.44 | 2021 | |
| Pfizer INC. | $33.76 | 2019-2023 | |
| Axonics, INC. | $28.42 | 2024 | Axonics |
| Organon LLC | $23.75 | 2022-2023 | Jada System |
| Supernus Pharmaceuticals, INC. | $20.56 | 2025 | Qelbree |
| Monaghan Medical Corporation | $17.53 | 2023 | Aerobika |
| Novo Nordisk INC | $16.55 | 2023 | Wegovy |
| Scynexis, INC. | $16.14 | 2022 | |
| Coopersurgical, INC. | $15.73 | 2020 | |
| Lupin INC. | $14.67 | 2020 | |
| Merck Sharp & Dohme LLC | $13.02 | 2022 | |
| Minerva Surgical, INC | $12.89 | 2019 | |
| Meditrina | $12.85 | 2023 | |
| Allergan, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Moersch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.